表紙
市場調査レポート

後天的遺伝子変異または後天的染色体変異:パイプライン製品の分析

Acquired Gene or Chromosome Alterations - Pipeline Review, 2015

発行 GlobalData 商品コード 342294
出版日 ページ情報 英文 348 Pages
即納可能
価格
本日の銀行送金レート: 1USD=104.18円で換算しております。
Back to Top
後天的遺伝子変異または後天的染色体変異:パイプライン製品の分析 Acquired Gene or Chromosome Alterations - Pipeline Review, 2015
出版日: 2015年10月01日 ページ情報: 英文 348 Pages
概要

当レポートでは、現在開発段階にあるの後天的遺伝子変異または後天的染色体変異向け遺伝子検査について調査し、パイプライン製品および様々な開発段階にある製品の包括的情報を提供しており、パイプライン製品開発に関与する主要企業のレビュー、進行中の臨床試験に関する情報 (試験フェーズ、試験状況、試験の開始・終了日など) 、および主な遺伝子検査の試験数などに関する情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 開発中の製品

  • パイプライン製品:開発段階別
  • パイプライン製品:地域別
  • パイプライン製品:規制経路別
  • パイプライン製品:承認時期別 (推定)

第4章 後天的遺伝子または染色体変異:開発中のパイプライン製品

  • 企業 - パイプライン製品:開発段階別
  • パイプライン製品:開発段階別

第5章後天的遺伝子または染色体変異:

  • 企業・製品の概要
  • Abbott Diagnostics
  • Agendia NV
  • AltheaDx, Inc.
  • Amarantus Bioscience Holdings, Inc.
  • AstraZeneca Plc
  • AutoGenomics, Inc.
  • Biocept, Inc.
  • Cepheid
  • Chinese University of Hong Kong
  • Columbia University
  • Dana-Farber Cancer Institute, Inc.
  • DiaCarta
  • Exosome Diagnostics, Inc.
  • Gencurix Co., Ltd.
  • GeneFirst Ltd
  • GenMark Diagnostics, Inc.
  • Genomic Health, Inc.
  • Genomic Vision
  • GenomicTree, Inc.
  • German Cancer Research Center
  • H. Lee Moffitt Cancer Center & Research Institute, Inc.
  • Harvard University
  • Helmholtz Centre for Infection Research
  • HistoRx, Inc. (Inactive)
  • Illumina, Inc.
  • Insight Genetics, Inc.
  • InVivoScribe Technologies, Inc.
  • Med BioGene Inc.
  • Merrimack Pharmaceuticals, Inc.
  • MolecularMD, Corp.
  • Multiplicom N.V.
  • Myriad Genetics, Inc.
  • Nanosphere, Inc.
  • New York University
  • NIH Office of Technology Transfer
  • Oryzon Genomics S.A.
  • Oxford Biodynamics Limited
  • Panagene Inc.
  • Pangaea Biotech, S.L.
  • PDI, lnc.
  • PharmaSeq, Inc.
  • Qiagen N.V.
  • RedPath Integrated Pathology, Inc.
  • Response Genetics, Inc.
  • Rheonix, Inc.
  • Seegene, Inc.
  • Shuwen Biotech Co. Ltd.
  • Syamala Srinivasa Life Sciences Pvt. Ltd
  • Sygnis AG
  • Sysmex Corporation
  • The Johns Hopkins University
  • thromboDx
  • Transbiomed, SL
  • Transgenomic, Inc.
  • TrovaGene, Inc.
  • University of California, Irvine
  • Vela Diagnostics
  • Xiamen Zeesan Biotech Co.,Ltd

第6章 後天的遺伝子または染色体変異:近年の発展

第7章 付録

図表一覧

目次
Product Code: GDME0077EPD

GlobalData's Medical Devices sector report, "Acquired Gene or Chromosome Alterations - Pipeline Review, 2015" provides an overview of genetic tests for Acquired Gene or Chromosome Alterations currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key genetic tests for Acquired Gene or Chromosome Alterations pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the genetic tests for Acquired Gene or Chromosome Alterations under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of genetic tests for Acquired Gene or Chromosome Alterations and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of genetic tests for Acquired Gene or Chromosome Alterations under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Acquired Gene or Chromosome Alterations Overview

3. Products under Development

  • 3.1. Acquired Gene or Chromosome Alterations - Pipeline Products by Stage of Development
  • 3.2. Acquired Gene or Chromosome Alterations - Pipeline Products by Territory
  • 3.3. Acquired Gene or Chromosome Alterations - Pipeline Products by Regulatory Path
  • 3.4. Acquired Gene or Chromosome Alterations - Pipeline Products by Estimated Approval Date

4. Acquired Gene or Chromosome Alterations - Pipeline Products under Development by Companies

  • 4.1. Acquired Gene or Chromosome Alterations Companies - Pipeline Products by Stage of Development
  • 4.2. Acquired Gene or Chromosome Alterations - Pipeline Products by Stage of Development

5. Acquired Gene or Chromosome Alterations Companies and Product Overview

  • 5.1. Abbott Diagnostics Company Overview
    • 5.1.1. Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview
  • 5.2. Agendia NV Company Overview
    • 5.2.1. Agendia NV Pipeline Products & Ongoing Clinical Trials Overview
  • 5.3. AltheaDx, Inc. Company Overview
    • 5.3.1. AltheaDx, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.4. Amarantus Bioscience Holdings, Inc. Company Overview
    • 5.4.1. Amarantus Bioscience Holdings, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.5. AstraZeneca Plc Company Overview
    • 5.5.1. AstraZeneca Plc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.6. AutoGenomics, Inc. Company Overview
    • 5.6.1. AutoGenomics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.7. Biocept, Inc. Company Overview
    • 5.7.1. Biocept, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.8. Cepheid Company Overview
    • 5.8.1. Cepheid Pipeline Products & Ongoing Clinical Trials Overview
  • 5.9. Chinese University of Hong Kong Company Overview
    • 5.9.1. Chinese University of Hong Kong Pipeline Products & Ongoing Clinical Trials Overview
  • 5.10. Columbia University Company Overview
    • 5.10.1. Columbia University Pipeline Products & Ongoing Clinical Trials Overview
  • 5.11. Dana-Farber Cancer Institute, Inc. Company Overview
    • 5.11.1. Dana-Farber Cancer Institute, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.12. DiaCarta Company Overview
    • 5.12.1. DiaCarta Pipeline Products & Ongoing Clinical Trials Overview
  • 5.13. Exosome Diagnostics, Inc. Company Overview
    • 5.13.1. Exosome Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.14. Gencurix Co., Ltd. Company Overview
    • 5.14.1. Gencurix Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.15. GeneFirst Ltd Company Overview
    • 5.15.1. GeneFirst Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • 5.16. GenMark Diagnostics, Inc. Company Overview
    • 5.16.1. GenMark Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.17. Genomic Health, Inc. Company Overview
    • 5.17.1. Genomic Health, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.18. Genomic Vision Company Overview
    • 5.18.1. Genomic Vision Pipeline Products & Ongoing Clinical Trials Overview
  • 5.19. GenomicTree, Inc. Company Overview
    • 5.19.1. GenomicTree, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.20. German Cancer Research Center Company Overview
    • 5.20.1. German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview
  • 5.21. H. Lee Moffitt Cancer Center & Research Institute, Inc. Company Overview
    • 5.21.1. H. Lee Moffitt Cancer Center & Research Institute, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.22. Harvard University Company Overview
    • 5.22.1. Harvard University Pipeline Products & Ongoing Clinical Trials Overview
  • 5.23. Helmholtz Centre for Infection Research Company Overview
    • 5.23.1. Helmholtz Centre for Infection Research Pipeline Products & Ongoing Clinical Trials Overview
  • 5.24. HistoRx, Inc. (Inactive) Company Overview
    • 5.24.1. HistoRx, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
  • 5.25. Illumina, Inc. Company Overview
    • 5.25.1. Illumina, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.26. Insight Genetics, Inc. Company Overview
    • 5.26.1. Insight Genetics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.27. InVivoScribe Technologies, Inc. Company Overview
    • 5.27.1. InVivoScribe Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.28. Med BioGene Inc. Company Overview
    • 5.28.1. Med BioGene Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.29. Merrimack Pharmaceuticals, Inc. Company Overview
    • 5.29.1. Merrimack Pharmaceuticals, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.30. MolecularMD, Corp. Company Overview
    • 5.30.1. MolecularMD, Corp. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.31. Multiplicom N.V. Company Overview
    • 5.31.1. Multiplicom N.V. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.32. Myriad Genetics, Inc. Company Overview
    • 5.32.1. Myriad Genetics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.33. Nanosphere, Inc. Company Overview
    • 5.33.1. Nanosphere, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.34. New York University Company Overview
    • 5.34.1. New York University Pipeline Products & Ongoing Clinical Trials Overview
  • 5.35. NIH Office of Technology Transfer Company Overview
    • 5.35.1. NIH Office of Technology Transfer Pipeline Products & Ongoing Clinical Trials Overview
  • 5.36. Oryzon Genomics S.A. Company Overview
    • 5.36.1. Oryzon Genomics S.A. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.37. Oxford Biodynamics Limited Company Overview
    • 5.37.1. Oxford Biodynamics Limited Pipeline Products & Ongoing Clinical Trials Overview
  • 5.38. Panagene Inc. Company Overview
    • 5.38.1. Panagene Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.39. Pangaea Biotech, S.L. Company Overview
    • 5.39.1. Pangaea Biotech, S.L. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.40. PDI, lnc. Company Overview
    • 5.40.1. PDI, lnc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.41. PharmaSeq, Inc. Company Overview
    • 5.41.1. PharmaSeq, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.42. Qiagen N.V. Company Overview
    • 5.42.1. Qiagen N.V. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.43. RedPath Integrated Pathology, Inc. Company Overview
    • 5.43.1. RedPath Integrated Pathology, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.44. Response Genetics, Inc. Company Overview
    • 5.44.1. Response Genetics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.45. Rheonix, Inc. Company Overview
    • 5.45.1. Rheonix, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.46. Seegene, Inc. Company Overview
    • 5.46.1. Seegene, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.47. Shuwen Biotech Co. Ltd. Company Overview
    • 5.47.1. Shuwen Biotech Co. Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.48. Syamala Srinivasa Life Sciences Pvt. Ltd Company Overview
    • 5.48.1. Syamala Srinivasa Life Sciences Pvt. Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • 5.49. Sygnis AG Company Overview
    • 5.49.1. Sygnis AG Pipeline Products & Ongoing Clinical Trials Overview
  • 5.50. Sysmex Corporation Company Overview
    • 5.50.1. Sysmex Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • 5.51. The Johns Hopkins University Company Overview
    • 5.51.1. The Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview
  • 5.52. thromboDx Company Overview
    • 5.52.1. thromboDx Pipeline Products & Ongoing Clinical Trials Overview
  • 5.53. Transbiomed, SL Company Overview
    • 5.53.1. Transbiomed, SL Pipeline Products & Ongoing Clinical Trials Overview
  • 5.54. Transgenomic, Inc. Company Overview
    • 5.54.1. Transgenomic, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.55. TrovaGene, Inc. Company Overview
    • 5.55.1. TrovaGene, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.56. University of California, Irvine Company Overview
    • 5.56.1. University of California, Irvine Pipeline Products & Ongoing Clinical Trials Overview
  • 5.57. Vela Diagnostics Company Overview
    • 5.57.1. Vela Diagnostics Pipeline Products & Ongoing Clinical Trials Overview
  • 5.58. Xiamen Zeesan Biotech Co.,Ltd Company Overview
    • 5.58.1. Xiamen Zeesan Biotech Co.,Ltd Pipeline Products & Ongoing Clinical Trials Overview

6. Acquired Gene or Chromosome Alterations- Recent Developments

7. Appendix

  • 7.1. Methodology
  • 7.2. About GlobalData
  • 7.3. Contact Us
  • 7.4. Disclaimer

List of Tables

  • Table 1: Acquired Gene or Chromosome Alterations - Pipeline Products by Stage of Development
  • Table 2: Acquired Gene or Chromosome Alterations - Pipeline Products by Territory
  • Table 3: Acquired Gene or Chromosome Alterations - Pipeline Products by Regulatory Path
  • Table 4: Acquired Gene or Chromosome Alterations - Pipeline Products by Estimated Approval Date
  • Table 5: Acquired Gene or Chromosome Alterations Companies - Pipeline Products by Stage of Development
  • Table 6: Acquired Gene or Chromosome Alterations - Pipeline Products by Stage of Development
  • Table 7: Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview
  • Table 8: 13q14.3 Companion Diagnostic Assay - Chronic Lymphocytic Leukemia - Product Status
  • Table 9: 13q14.3 Companion Diagnostic Assay - Chronic Lymphocytic Leukemia - Product Description
  • Table 10: AKT Companion Diagnostic Assay - Renal Cancer - Product Status
  • Table 11: AKT Companion Diagnostic Assay - Renal Cancer - Product Description
  • Table 12: ALK Companion Diagnostic Assay - Colorectal Cancer - Product Status
  • Table 13: ALK Companion Diagnostic Assay - Colorectal Cancer - Product Description
  • Table 14: AR Companion Diagnostic Assay - Prostate Cancer - Product Status
  • Table 15: AR Companion Diagnostic Assay - Prostate Cancer - Product Description
  • Table 16: ATM Companion Diagnostic Assay - Chronic Lymphocytic Leukemia - Product Status
  • Table 17: ATM Companion Diagnostic Assay - Chronic Lymphocytic Leukemia - Product Description
  • Table 18: AURKA Companion Diagnostic Assay - Prostate Cancer - Product Status
  • Table 19: AURKA Companion Diagnostic Assay - Prostate Cancer - Product Description
  • Table 20: AXL Companion Diagnostic Assay - Lung Cancer - Product Status
  • Table 21: AXL Companion Diagnostic Assay - Lung Cancer - Product Description
  • Table 22: BCL2 Companion Diagnostic Assay - Leukemia - Product Status
  • Table 23: BCL2 Companion Diagnostic Assay - Leukemia - Product Description
  • Table 24: BCL2 Companion Diagnostic Assay - Lymphoma - Product Status
  • Table 25: BCL2 Companion Diagnostic Assay - Lymphoma - Product Description
  • Table 26: BCL6 Companion Diagnostic Assay - Lymphoma - Product Status
  • Table 27: BCL6 Companion Diagnostic Assay - Lymphoma - Product Description
  • Table 28: BRAF Companion Diagnostic Assay - Colon Cancer - Product Status
  • Table 29: BRAF Companion Diagnostic Assay - Colon Cancer - Product Description
  • Table 30: BRAF Companion Diagnostic Assay - Gastric Cancer - Product Status
  • Table 31: BRAF Companion Diagnostic Assay - Gastric Cancer - Product Description
  • Table 32: BRAF Companion Diagnostic Assay - Glioblastoma - Product Status
  • Table 33: BRAF Companion Diagnostic Assay - Glioblastoma - Product Description
  • Table 34: BRAF Companion Diagnostic Assay - Lung Cancer - Product Status
  • Table 35: BRAF Companion Diagnostic Assay - Lung Cancer - Product Description
  • Table 36: BRAF Companion Diagnostic Assay - Melanoma - Product Status
  • Table 37: BRAF Companion Diagnostic Assay - Melanoma - Product Description
  • Table 38: BRAF Companion Diagnostic Assay - Ovarian Cancer - Product Status
  • Table 39: BRAF Companion Diagnostic Assay - Ovarian Cancer - Product Description
  • Table 40: BRCA1 Companion Diagnostic Assay - Ovarian Cancer - Product Status
  • Table 41: BRCA1 Companion Diagnostic Assay - Ovarian Cancer - Product Description
  • Table 42: BRCA2 Companion Diagnostic Assay - Ovarian Cancer - Product Status
  • Table 43: BRCA2 Companion Diagnostic Assay - Ovarian Cancer - Product Description
  • Table 44: CCND1 Companion Diagnostic Assay - Lymphoma - Product Status
  • Table 45: CCND1 Companion Diagnostic Assay - Lymphoma - Product Description
  • Table 46: CDKN2A Companion Diagnostic Assay - Bladder Cancer - Product Status
  • Table 47: CDKN2A Companion Diagnostic Assay - Bladder Cancer - Product Description
  • Table 48: CDKN2C Companion Diagnostic Assay - Multiple Myeloma - Product Status
  • Table 49: CDKN2C Companion Diagnostic Assay - Multiple Myeloma - Product Description
  • Table 50: Chromosome 12 Companion Diagnostic Assay - Chronic Lymphocytic Leukemia - Product Status
  • Table 51: Chromosome 12 Companion Diagnostic Assay - Chronic Lymphocytic Leukemia - Product Description
  • Table 52: Chromosome 17 Companion Diagnostic Assay - Acute Lymphocytic Leukemia - Product Status
  • Table 53: Chromosome 17 Companion Diagnostic Assay - Acute Lymphocytic Leukemia - Product Description
  • Table 54: Chromosome 4 Companion Diagnostic Assay - Acute Lymphocytic Leukemia - Product Status
  • Table 55: Chromosome 4 Companion Diagnostic Assay - Acute Lymphocytic Leukemia - Product Description
  • Table 56: Chromosome 7 Companion Diagnostic Assay - Acute Lymphocytic Leukemia - Product Status
  • Table 57: Chromosome 7 Companion Diagnostic Assay - Acute Lymphocytic Leukemia - Product Description
  • Table 58: Chromosome 7 Companion Diagnostic Assay - Acute Myeloid Leukemia - Product Status
  • Table 59: Chromosome 7 Companion Diagnostic Assay - Acute Myeloid Leukemia - Product Description
  • Table 60: Chromosome 8 Companion Diagnostic Assay - Acute Myeloid Leukemia - Product Status
  • Table 61: Chromosome 8 Companion Diagnostic Assay - Acute Myeloid Leukemia - Product Description
  • Table 62: Chromosome X Companion Diagnostic Assay - Cervical Cancer - Product Status
  • Table 63: Chromosome X Companion Diagnostic Assay - Cervical Cancer - Product Description
  • Table 64: CKS1B Companion Diagnostic Assay - Multiple Myeloma - Product Status
  • Table 65: CKS1B Companion Diagnostic Assay - Multiple Myeloma - Product Description
  • Table 66: COT Companion Diagnostic Assay - Melanoma - Product Status
  • Table 67: COT Companion Diagnostic Assay - Melanoma - Product Description
  • Table 68: CRAF Companion Diagnostic Assay - Melanoma - Product Status
  • Table 69: CRAF Companion Diagnostic Assay - Melanoma - Product Description
  • Table 70: D5S721 Companion Diagnostic Assay - Acute Myeloid Leukemia - Product Status
  • Table 71: D5S721 Companion Diagnostic Assay - Acute Myeloid Leukemia - Product Description
  • Table 72: D7S486 Companion Diagnostic Assay - Acute Myeloid Leukemia - Product Status
  • Table 73: D7S486 Companion Diagnostic Assay - Acute Myeloid Leukemia - Product Description
  • Table 74: D7S552 Companion Diagnostic Assay - Acute Myeloid Leukemia - Product Status
  • Table 75: D7S552 Companion Diagnostic Assay - Acute Myeloid Leukemia - Product Description
  • Table 76: DCC Companion Diagnostic Assay - Colorectal Cancer - Product Status
  • Table 77: DCC Companion Diagnostic Assay - Colorectal Cancer - Product Description
  • Table 78: DDR2 Companion Diagnostic Assay - Lung Cancer - Product Status
  • Table 79: DDR2 Companion Diagnostic Assay - Lung Cancer - Product Description
  • Table 80: del(13q) Companion Diagnostic Assay - Myelodysplastic Syndrome - Product Status
  • Table 81: del(13q) Companion Diagnostic Assay - Myelodysplastic Syndrome - Product Description
  • Table 82: del(17p) Companion Diagnostic Assay - Chronic Lymphocytic Leukemia - Product Status
  • Table 83: del(17p) Companion Diagnostic Assay - Chronic Lymphocytic Leukemia - Product Description
  • Table 84: del(17p) Companion Diagnostic Assay - Multiple Myeloma - Product Status
  • Table 85: del(17p) Companion Diagnostic Assay - Multiple Myeloma - Product Description
  • Table 86: del(5q) Companion Diagnostic Assay - Myelodysplastic Syndrome - Product Status
  • Table 87: del(5q) Companion Diagnostic Assay - Myelodysplastic Syndrome - Product Description
  • Table 88: del(7q) Companion Diagnostic Assay - Myelodysplastic Syndrome - Product Status
  • Table 89: del(7q) Companion Diagnostic Assay - Myelodysplastic Syndrome - Product Description
  • Table 90: del(9q) Companion Diagnostic Assay - Myelodysplastic Syndrome - Product Status
  • Table 91: del(9q) Companion Diagnostic Assay - Myelodysplastic Syndrome - Product Description
  • Table 92: EGFR Companion Diagnostic Assay - Brain Cancer - Product Status
  • Table 93: EGFR Companion Diagnostic Assay - Brain Cancer - Product Description
  • Table 94: EGFR Companion Diagnostic Assay - Glioblastoma - Product Status
  • Table 95: EGFR Companion Diagnostic Assay - Glioblastoma - Product Description
  • Table 96: EGFR Companion Diagnostic Assay - Lung Cancer - Product Status
  • Table 97: EGFR Companion Diagnostic Assay - Lung Cancer - Product Description
  • Table 98: EGFRvIII Companion Diagnostic Assay - Glioblastoma - Product Status
  • Table 99: EGFRvIII Companion Diagnostic Assay - Glioblastoma - Product Description
  • Table 100: EGFRvIII Companion Diagnostic Assay - Lung Cancer - Product Status
  • Table 101: EGFRvIII Companion Diagnostic Assay - Lung Cancer - Product Description
  • Table 102: ERBB3 Companion Diagnostic Assay - Bladder Cancer - Product Status
  • Table 103: ERBB3 Companion Diagnostic Assay - Bladder Cancer - Product Description
  • Table 104: ETV Companion Diagnostic Assay - Sarcoma - Product Status
  • Table 105: ETV Companion Diagnostic Assay - Sarcoma - Product Description
  • Table 106: FGFR1 Companion Diagnostic Assay - Prostate Cancer - Product Status
  • Table 107: FGFR1 Companion Diagnostic Assay - Prostate Cancer - Product Description
  • Table 108: FGFR2 Companion Diagnostic Assay - Colorectal Cancer - Product Status
  • Table 109: FGFR2 Companion Diagnostic Assay - Colorectal Cancer - Product Description
  • Table 110: FGFR2 Companion Diagnostic Assay - Gastric Cancer - Product Status
  • Table 111: FGFR2 Companion Diagnostic Assay - Gastric Cancer - Product Description
  • Table 112: FGFR2 Companion Diagnostic Assay - Lung Cancer - Product Status
  • Table 113: FGFR2 Companion Diagnostic Assay - Lung Cancer - Product Description
  • Table 114: FGFR3 Companion Diagnostic Assay - Bladder Cancer - Product Status
  • Table 115: FGFR3 Companion Diagnostic Assay - Bladder Cancer - Product Description
  • Table 116: FGFR3-TACC3 Companion Diagnostic Assay - Lung Cancer - Product Status
  • Table 117: FGFR3-TACC3 Companion Diagnostic Assay - Lung Cancer - Product Description
  • Table 118: GNA11 Companion Diagnostic Assay - Melanoma - Product Status
  • Table 119: GNA11 Companion Diagnostic Assay - Melanoma - Product Description
  • Table 120: GNAQ Companion Diagnostic Assay - Melanoma - Product Status
  • Table 121: GNAQ Companion Diagnostic Assay - Melanoma - Product Description

List of Figures

  • Figure 1: Acquired Gene or Chromosome Alterations - Pipeline Products by Stage of Development
  • Figure 2: Acquired Gene or Chromosome Alterations - Pipeline Products by Territory
  • Figure 3: Acquired Gene or Chromosome Alterations - Pipeline Products by Regulatory Path
  • Figure 4: Acquired Gene or Chromosome Alterations - Pipeline Products by Estimated Approval Date
Back to Top